Krystal Biotech, Inc. Krystal Biotech, Inc.

Krystal Biotech, Inc.

KRYS

Classement en actions #2123
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Prix de l'action
$322.07
Dernière synchronisation: 2026-10-21
Capitalisation boursière
$9.53B
Changement (1 jour)
-1.03%
Changement (1 an)
72.76%
Pays
US
Échange Krystal Biotech, Inc. (KRYS)

Catégorie

Healthcare
Historique du prix de l'action pour Krystal Biotech, Inc. (KRYS)
Prix de clôture le plus élevé : $326.06 le 2026-10-01

Prix de clôture le plus bas : $10.08 le 2017-09-01
Historique du prix de l'action de Krystal Biotech, Inc. de 2017 à 2026
Performance annuelle du prix de l'action
Année Performance
2026 (TTM) 20.87%
2025 39.10%
2024 50.07%
2023 49.77%
2022 7.69%
2021 22.40%
2020 -4.80%
2019 169.14%
2018 129.54%
2017 0.00%
Prix de l'action pour des entreprises similaires ou concurrentes
Entreprise Prix de l'action Variation 1a% Pays
$527.18 23.62%
US
$251.29 835.90%
US
$137.83 -3.78%
AU
$890.85 9.42%
NL
$760.15 8.04%
CH